New Agents Committee (NAC)

Cancer Research UK's New Agents Committee (NAC) meets quarterly and is run by the Drug Development Office. It provides a one-step process for selecting new anti-cancer treatments and taking them into early clinical trials.

All submission to and meetings of the NAC are confidential.

Membership includes:

• Clinical representatives from many Key UK Clinical Centres where early/Phase I clinical trials are carried out
• Other experts in cancer drug development
• Representatives of the CDP Scientific Advisory Board (SAB)

NAC specialist preclinical and clinical expertise includes:

• drug discovery and development of small molecules and biologicals
• clinical trial design, pharmacokinetics, pharmacodynamics, functional imaging and spectroscopy
• chemistry, clinical pharmacology, radiolabelling, pharmaceutical and formulation development
• molecular biology and immunology
• toxicology
• past industry experience

See the Cancer Research UK Funding & Research website for more information about the committee.